BioTime Inc. (BTX)

2.64
0.27 11.00
AMEX : Health Technology
Prev Close 2.37
Open 2.41
Day Low/High 2.35 / 2.61
52 Wk Low/High 1.98 / 3.16
Volume 1.48M
Avg Volume 356.30K
Exchange AMEX
Shares Outstanding 126.87M
Market Cap 299.42M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
BioTime, Inc. Announces The Appointment Of Life Sciences Industry Veteran Russell Skibsted As Chief Financial Officer

BioTime, Inc. Announces The Appointment Of Life Sciences Industry Veteran Russell Skibsted As Chief Financial Officer

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the Company's Board of Directors has appointed Russell Skibsted...

Short Interest Jumps 11.8% For BTX

Short Interest Jumps 11.8% For BTX

The most recent short interest data has been released by the NASDAQ for the 10/30/2015 settlement date, which shows a 826,152 share increase in total short interest for BioTime, Inc. , to 7,838,190, an increase of 11.78% since 10/15/2015.

Insider Trading Alert - TIPT, BTX And WASH Traded By Insiders

Insider Trading Alert - TIPT, BTX And WASH Traded By Insiders

Stocks with insider trader activity include TIPT, BTX and WASH

BioTime, Inc. Reports Third Quarter 2015 Results And Recent Corporate Accomplishments

BioTime, Inc. Reports Third Quarter 2015 Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT and TASE:BTX) today reported financial results for the third quarter ended September 30, 2015 and provided an update on its recent accomplishments.

BioTime, Inc. And Hepregen Corporation Form Ascendance Biotechnology, Inc. To Address The In Vitro Cell Biology Market

BioTime, Inc. And Hepregen Corporation Form Ascendance Biotechnology, Inc. To Address The In Vitro Cell Biology Market

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company, and Hepregen Corporation, a privately held company engaged in the development and marketing of proprietary drug screening products,...

Adi Mohanty Joins Michael D. West, PhD, As Co-CEO Of BioTime, Inc.

Adi Mohanty Joins Michael D. West, PhD, As Co-CEO Of BioTime, Inc.

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, reported today that its Board of Directors has appointed Adi Mohanty to serve...

BioTime's Subsidiary OncoCyte Corporation Files Form 10 Registration Statement For Planned Distribution

BioTime's Subsidiary OncoCyte Corporation Files Form 10 Registration Statement For Planned Distribution

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, and its subsidiary OncoCyte Corporation ("OncoCyte"), today announced that OncoCyte...

BioTime, Inc. Agrees To Sell $5.1 Million Of Equity

BioTime, Inc. Agrees To Sell $5.1 Million Of Equity

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it has agreed to sell 1,600,000 of its common shares, no par...

BioTime Announces The Closing Of A $20 Million Direct Registered Offering; Demand Exceeds NIS 80 Million Offered

BioTime Announces The Closing Of A $20 Million Direct Registered Offering; Demand Exceeds NIS 80 Million Offered

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that BioTime completed a registered direct offering of 6,530,612...

Heraeus Medical GmbH And BioTime Subsidiary OrthoCyte Corporation Enter Into Exclusive Worldwide Development And Licensing Agreements

Heraeus Medical GmbH And BioTime Subsidiary OrthoCyte Corporation Enter Into Exclusive Worldwide Development And Licensing Agreements

Heraeus Medical GmbH, one of the leading companies in the field of bone cement and biomaterials for elective orthopedic and trauma surgery, and BioTime, Inc.

Mount Sinai And LifeMap Solutions Announce Initial Results For Asthma Health App And New Features To Enhance Clinical Impact

Mount Sinai And LifeMap Solutions Announce Initial Results For Asthma Health App And New Features To Enhance Clinical Impact

The Icahn School of Medicine at Mount Sinai and LifeMap Solutions, a digital-health subsidiary of BioTime, Inc.

BioTime's Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track Designation For OpRegen® for The Treatment Of The Dry Form Of Age-Related Macular Degeneration

BioTime's Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track Designation For OpRegen® for The Treatment Of The Dry Form Of Age-Related Macular Degeneration

BioTime, Inc. (NYSE MKT and TASE: BTX) and its subsidiary Cell Cure Neurosciences Ltd.

BioTime, Inc. Agrees To Sell Up To $20.7 Million Of Common Shares

BioTime, Inc. Agrees To Sell Up To $20.7 Million Of Common Shares

BioTime, Inc. (NYSE MKT and TASE: BTX) today announced that it has agreed to sell up to $20.

BioTime Subsidiary OncoCyte Corporation Appoints Cavan Redmond To Its Board Of Directors

BioTime Subsidiary OncoCyte Corporation Appoints Cavan Redmond To Its Board Of Directors

BioTime, Inc. (NYSE MKT and TASE: BTX) announced the appointment of Cavan Redmond as an independent member of the Board of Directors of BioTime's subsidiary OncoCyte Corporation.

BioTime, Inc. Agrees To Sell $8.58 Million Of Common Shares

BioTime, Inc. Agrees To Sell $8.58 Million Of Common Shares

BioTime, Inc. (NYSE MKT and TASE: BTX) today announced that it has agreed to sell 2,607,401 of its common shares, no par value, at an offering price of $3.

BioTime Announces Dual Listing On The Tel Aviv Stock Exchange

BioTime Announces Dual Listing On The Tel Aviv Stock Exchange

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company focused on the development and commercialization of cell-based therapies, announced today that the Tel Aviv Stock Exchange (TASE) has approved the new listing of...

BioTime Chief Executive Officer Dr. Michael D. West To Be Keynote Speaker At Stem Cells & Regenerative Medicine Congress 2015

BioTime Chief Executive Officer Dr. Michael D. West To Be Keynote Speaker At Stem Cells & Regenerative Medicine Congress 2015

BioTime, Inc. (NYSE MKT:BTX) announced today that its Chief Executive Officer Michael D.

BioTime Management To Present At Rodman & Renshaw 17th Annual Global Investment Conference

BioTime Management To Present At Rodman & Renshaw 17th Annual Global Investment Conference

BioTime, Inc. (NYSE MKT:BTX) announced today that BioTime management will present at the Rodman & Renshaw 17th Annual Investment Conference in New York City from 3:00 to 3:25 p.

Insider Trading Alert - ASYS, BTX And STAG Traded By Insiders

Insider Trading Alert - ASYS, BTX And STAG Traded By Insiders

Stocks with insider trader activity include ASYS, BTX and STAG

The Wistar Institute And BioTime Subsidiary OncoCyte Corporation Expand Agreement To Develop Molecular Diagnostic Test For The Detection Of Lung Cancer

The Wistar Institute And BioTime Subsidiary OncoCyte Corporation Expand Agreement To Develop Molecular Diagnostic Test For The Detection Of Lung Cancer

The Wistar Institute and BioTime, Inc. (NYSE MKT: BTX) announced that Wistar and BioTime's subsidiary OncoCyte Corporation, have expanded their collaborative relationship to develop a simple, non-invasive, blood-based test...

BioTime, Inc. Reports Second Quarter 2015 Results And Recent Developments

BioTime, Inc. Reports Second Quarter 2015 Results And Recent Developments

BioTime, Inc. (NYSE MKT:BTX) today reported financial results for the second quarter ended June 30, 2015 and provided a corporate update.

BioTime Announces The Issuance Of 27 New Patents Protecting Stem Cell-Based Product Development

BioTime Announces The Issuance Of 27 New Patents Protecting Stem Cell-Based Product Development

BioTime, Inc. (NYSE MKT:BTX) today announced that 27 new patents have issued during the first half of 2015 that are owned or licensed to BioTime or its subsidiaries.

OncoCyte Announces Appointment Of Andy Arno To Board Of Directors

OncoCyte Announces Appointment Of Andy Arno To Board Of Directors

OncoCyte Corporation, a cancer diagnostics company and a member of the BioTime, Inc.

First Week of July 17th Options Trading For BioTime (BTX)

First Week of July 17th Options Trading For BioTime (BTX)

Investors in BioTime, Inc. saw new options begin trading this week, for the July 17th expiration.

William Annett Named Chief Executive Officer Of OncoCyte Corporation

William Annett Named Chief Executive Officer Of OncoCyte Corporation

OncoCyte Corporation, a cancer diagnostics company and a member of the BioTime, Inc.

BioTime To Present At The Jefferies 2015 Global Healthcare Conference

BioTime To Present At The Jefferies 2015 Global Healthcare Conference

BioTime, Inc. (NYSE MKT: BTX) today announced that Chief Executive Officer Michael D.

OncoCyte's Collaborators At The Wistar Institute Present Positive Clinical Interim Results Of Blood-Based Diagnostic Test For Non-Invasive Detection Of Lung Cancer

OncoCyte's Collaborators At The Wistar Institute Present Positive Clinical Interim Results Of Blood-Based Diagnostic Test For Non-Invasive Detection Of Lung Cancer

BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced the presentation of positive interim clinical results demonstrating the high level of observed sensitivity and specificity in the assayed...

OncoCyte Corporation Completes Equity Financing Round

OncoCyte Corporation Completes Equity Financing Round

BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has received a new round of financing to fund further development and commercialization activities for its cancer diagnostic...

BioTime's Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.6 Million Grant From Israel's Office Of The Chief Scientist

BioTime's Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.6 Million Grant From Israel's Office Of The Chief Scientist

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd.

TheStreet Quant Rating: D (Sell)